Anti-Human IL-2Rα (CD25) (Basiliximab) [Clone Hu107] — Fc Muted™
Anti-Human IL-2Rα (CD25) (Basiliximab) [Clone Hu107] — Fc Muted™
Product No.: LT305
Product No.LT305 Clone Hu107 Target CD25 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names IL-2-RA; IL2-RA; TAC antigen; p55; CD25 Isotype Human IgG1κ Applications B , CyTOF® , FC , IF , IHC , WB |
Antibody DetailsProduct DetailsReactive Species Cynomolgus Monkey ⋅ Rhesus Monkey ⋅ Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Muted Immunogen Human CD25 Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping 2-8°C Wet Ice RRIDAB_2893951 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Basiliximab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? WB B IF IHC Additional Reported Applications For Relevant Conjugates ? CyTOF® Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Basiliximab. Basiliximab recognizes human CD25. This product is for research use only. Background CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2Rα. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25. Anti-Human IL-2R alpha (CD25) (Basiliximab) utilizes the same variable regions from the therapeutic antibody Basiliximab making it ideal for research projects. Antigen Distribution IL-2Rα is expressed on activated mature T and B lymphocytes, during early stages of thymocytes development, pre-B cells, and in activated CD4+ memory T-lymphocytes. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Role of Basiliximab Biosimilars in Pharmacokinetic (PK) Bridging ELISAOverview of Basiliximab Biosimilars Basiliximab biosimilars are used in various analytical studies, including pharmacokinetic (PK) bridging assays. These biosimilars are designed to mimic the structure and function of the reference product, in this case, Basiliximab, which is a monoclonal antibody used for immunosuppression in kidney transplant patients. Use in Pharmacokinetic (PK) Bridging ELISAIn PK bridging ELISAs, biosimilars can serve as calibration standards or reference controls to measure drug concentration in serum samples. Here's how they are utilized:
Implementation in PK Bridging ELISAStep-by-Step Process:
By using Basiliximab biosimilars as calibration standards and reference controls, researchers can effectively measure drug concentrations in serum samples during PK bridging ELISA assays. The primary in vivo models for administration of research-grade anti-CD25 antibodies to study tumor growth inhibition and characterize tumor-infiltrating lymphocytes (TILs) are syngeneic mouse models and, more recently, humanized mouse models. Key models and their features:
Less commonly used or supplementary models:
Summary Table
In both model types, TILs are isolated from tumors post-treatment and characterized with flow cytometry or histology for cell populations (CD8+, Tregs, etc.) and functional phenotypes. Conclusion: Synergistic Effects of Basiliximab Biosimilar with Other Checkpoint Inhibitors in Immune-Oncology ResearchBasiliximab Biosimilar: Mechanism and Role Basiliximab biosimilars are monoclonal antibodies that selectively block the CD25 subunit of the interleukin-2 receptor (IL-2Rα), thereby inhibiting T-cell activation without broadly depleting T cells. This targeted approach is distinct from traditional immunosuppressants and is especially relevant in transplantation and, increasingly, in immuno-oncology research, where precise control of T-cell function can be advantageous. Biosimilars are particularly valuable in preclinical and translational research due to their cost-effectiveness and reproducibility. Conceptual Basis for Combination Therapy in Immune-OncologyIn cancer immunotherapy, synergy is often sought by targeting multiple immune pathways simultaneously. For example, combining immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 has shown enhanced anti-tumor efficacy in both preclinical and clinical settings, as these agents act at different stages of the immune response—CTLA-4 inhibitors enhance T-cell priming in lymph nodes, while PD-1/PD-L1 inhibitors block T-cell exhaustion at the tumor site. Similarly, combinations of LAG-3 or TIM-3 inhibitors with PD-1/PD-L1 inhibitors are being explored, with clinical trials demonstrating improved outcomes in certain cancers. The rationale is that each agent addresses a unique immune evasion mechanism, potentially overcoming the limitations of monotherapy. Research Use of Basiliximab Biosimilar with Other Checkpoint InhibitorsCurrent Landscape While the primary clinical use of basiliximab is in transplantation, its biosimilars are increasingly employed in preclinical research to explore novel immunomodulatory strategies. The selective inhibition of IL-2 signaling by basiliximab biosimilars allows researchers to temporally modulate T-cell activation without full depletion, which may reduce toxicity risks compared to broad immunosuppressants. This property makes it an attractive candidate for combinatorial studies in complex immune-oncology models. Potential Synergies with Other Checkpoint Inhibitors
Experimental Considerations
Challenges and Future Directions
Summary Table: Potential Combinations and Research Questions
ConclusionResearchers use basiliximab biosimilars alongside other checkpoint inhibitors (e.g., anti-CTLA-4, anti-LAG-3) to explore whether selective, transient inhibition of T-cell proliferation can enhance the safety and efficacy of immune checkpoint blockade in complex oncology models. This approach is largely preclinical at present, with the goal of uncovering novel combinatorial strategies that maximize anti-tumor immunity while minimizing toxicity. The growing availability of biosimilars supports such innovative research, though clinical translation will require rigorous validation. A Basiliximab biosimilar can be used as either the capture or detection reagent in a bridging anti-drug antibody (ADA) ELISA to monitor a patient’s immune response against basiliximab by detecting antibodies generated against this therapeutic monoclonal antibody. Context and Mechanism:
How it works:
Why use a biosimilar instead of the reference product?
Summary Table: Basiliximab Biosimilar in Bridging ADA ELISA
Key Points:
Limitations and Considerations:
This method is widely used for post-marketing immunogenicity monitoring of both innovator and biosimilar biologics. References & CitationsTechnical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
|---|---|
LT300 | |
LT303 | |
LT304 | |
LT311 | |
LT305 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
